Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vue63
- Development stage
- Preclinical
- Lead developer
- 1Up Therapeutics
- Modality
- Small Molecules
01
Overview
Vue63 is a preclinical-stage small molecule therapeutic being developed by 1Up Therapeutics for the treatment of liver cancer, specifically hepatocellular carcinoma (HCC). The compound was identified through the company's discovery platform, which leverages genomic and molecular profiling to identify and target specific drivers of liver cancer progression. 1Up Therapeutics focuses on addressing high-risk molecular subtypes of the disease that are often resistant to current standard-of-care treatments. As of 2024, Vue63 remains in early development, and while its specific molecular target has not been publicly disclosed, it is part of a pipeline aimed at "undruggable" targets in the liver cancer landscape.
- Other names
- Vue63Vue-63Vue 63
Beyond the preview
Go deeper on Vue63.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vue63.